Weight often rebounds when you stop the medication
International Journal of Molecular Sciences 24
GLP-1MK-801 versus semaglutide To further scrutinize the translational potential of GLP-1MK-801, we benchmarked it against semaglutide, a pharmacokinetically optimized GLP-1 receptor agonist approved for treatment of obesity and clinically available as a once-weekly injectable 33
Notably, DXA-based body composition analysis showed ~9293% of weight loss was derived from fat mass, suggesting relative preservation of lean mass a key limitation of many current weight-loss strategies
Sources: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Gastroparesis Information Page: Mayo Clinic - Gastroparesis: American College of Gastroenterology - Gastroparesis: Bloomberg - FDA Warns of Gastroparesis Risk With Novo Nordisk's Ozempic:
Sun, Y., Zheng, Y., Wang, C